1. A compound of formula (I):
wherein
B is
(a) C3-8 cyloalkyl, phenyl, naphthyl, tetrahydronaphthyl, indenyl, or indanyl, wherein the C3-8 cyloalkyl, phenyl, naphthyl, tetrahydronaphthyl, indenyl, or indanyl is optionally substituted with one or more R5;
or
(b) 5-16 membered monocyclic, bicyclic, or tricyclic heterocyclyl, wherein the heterocyclyl is optionally substituted with one or more R6;
R1 is hydrogen, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C3-8-cycloalkyl, aryl, heteroaryl, aryl-C1-6-alkyl-, C3-8 cycloalkyl-C1-6-alkyl-, or heteroaryl-C1-6-alkyl-; wherein the R1C1-8-alkyl, C2-8-alkenyl, or C2-8-alkynyl, alone or as part of another moiety, is optionally substituted with one or more substituents independently selected from the group consisting of CN, NO2, halo, \u2014ORa, \u2014C(O)Ra, \u2014C(O)ORa, \u2014OC(O)Ra, \u2014NRbRc, \u2014NRbC(O)Ra, \u2014NHC(O)NHRb, \u2014C(O)NRbRc, \u2014NHSO2Ra, and \u2014SO2NRbNRc; and (b) the R1C3-8-cycloalkyl, aryl, or heteroaryl, alone or as part of another moiety, is optionally substituted with one or more substituents independently selected from the group consisting of C1-6-alkyl, C1-6-haloalkyl, C2-6-alkenyl, heterocycloalkyl, aryl, heteroaryl, halo, oxo, CN, NO2, \u2014ORd, \u2014C(O)Rd, \u2014C(O)ORd, \u2014OC(O)Rd, \u2014SRd, \u2014S(O)Rd, \u2014SO2Rd, \u2014NReRf, \u2014NHC(O)Re, \u2014NHC(O)NHRe, \u2014NHC(O)ORe, \u2014NHSO2Rd, \u2014C(O)NHRe, and \u2014SO2NHNRe;
R2 is hydrogen, halo, or C1-6-alkyl;
R3 is hydrogen, halo, C1-6-alkyl, C2-6-alkenyl, C3-8 cycloalkyl, C3-8 cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heteroaryl-C1-6-alkyl-, heterocycloalkyl-C1-6-alkyl-, C(O)R7, C(O)OR7, C(O)NR8R9, or \u2014C1-4-alkyl-NR10R11, wherein the R3C1-6-alkyl or C2-6-alkenyl, alone or as part of another moiety, is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, and C1-6-alkoxy, and wherein the R3C3-8 cycloalkyl, C3-8 cycloalkenyl, aryl, heteroaryl, or heterocycloalkyl, alone or as part of another moiety, is optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, and \u2014NRgRh;
or R2 and R3 can be joined together to form a 5-8 membered aryl or heterocyclic ring, wherein the ring is optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2;
R4 is hydrogen or C1-6-alkyl;
R5, at each occurrence, is independently CN, NO2, halo, C1-6-alkyl, C1-6-haloalkyl, ORi, SRi, C(O)Ri, C(O)NRjRk, C(O)ORi, NRjRk, NRjC(O)Ri, S(O)2Ri, NRjS(O)2Ri, S(O)2NRjRk, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, aryl-C1-6-alkyl-, cycloalkyl-C1-6-alkyl-, heteroaryl-C1-6-alkyl-, or heterocycloalkyl-C1-6-alkyl-; wherein the aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, alone or as part of another moiety, is optionally substituted with one or more R12;
R6, at each occurrence, is independently CN, NO2, halo, C1-6-alkyl, C1-6-haloalkyl, C1-4-alkyl-heterocycloalkyl-, \u2014C1-6-alkyl-N(C1-6-alkyl)2, ORl, C(O)Rl, C(O)NRmRn, C(O)ORl, NRmRn, NRlC(O)Rm, S(O)2R1, NRmS(O)2Rl, or S(O)2NRmRn;
R7, at each occurrence, is independently is hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, or heterocycloalkyl;
R8 and R9, at each occurrence, are independently hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, or heterocycloalkyl;
R10 and R11, at each occurrence, are independently hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, or heterocycloalkyl;
R12, at each occurrence, is independently is CN, NO2, halo, C1-6-alkyl, C1-6-haloalkyl, ORp, SRp, C(O)Rp, C(O)NRqRr, C(O)ORp, NRqRr, NRqC(O)Rp, S(O)2Rp, NRqS(O)2Rp, or S(O)2NRqRr;
Ra, at each occurrence, is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
Rb and Rc, at each occurrence, are independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
Rd, at each occurrence, is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
Re and Rf, at each occurrence, are independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
Rg and Rh, at each occurrence, are independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
Ri, at each occurrence, is independently selected from the group consisting of hydrogen, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl; wherein the C1-6alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C1-6-alkoxy, \u2014NH2, \u2014NHC1-6-alkyl, \u2014N(C1-6-alkyl)2, \u2014C(O)N(C1-6-alkyl)2; and wherein the aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2;
Rj and Rk, at each occurrence, are independently selected from the group consisting of hydrogen, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl; wherein the C1-6-alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C1-6-alkoxy, \u2014NH2, \u2014NHC1-6-alkyl, \u2014N(C1-6-alkyl)2, \u2014C(O)N(C1-6-alkyl)2, and wherein the aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2;
Rl, at each occurrence, is independently selected from the group consisting of hydrogen, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl; wherein the C1-6-alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C1-6-alkoxy, \u2014NH2, \u2014NHC1-6-alkyl, and \u2014N(C1-6-alkyl)2, and wherein the aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2;
Rm and Rn, at each occurrence, are independently selected from the group consisting of hydrogen, C1-6 alkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl; wherein the C1-6-alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C1-6-alkoxy, \u2014NH2, \u2014NHC1-6-alkyl, and \u2014N(C1-6-alkyl)2, and wherein the aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2;
Rp, at each occurrence, is independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl; and
Rq and Rr, at each occurrence, are independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl;
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is C1-8-alkyl or C2-8-alkenyl, wherein the C1-8-alkyl or C2-8-alkenyl is optionally substituted with one, two, or three substituents independently selected from the group consisting of CN, NO2, halo, \u2014ORa, \u2014C(O)Ra, \u2014C(O)ORa, \u2014OC(O)Ra, \u2014NRbRc, \u2014NRbC(O)Ra, \u2014NHC(O)NHRb, \u2014C(O)NRbRc, \u2014NHSO2Ra, and \u2014SO2NRbNRc.
3. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is phenyl, wherein the phenyl is optionally substituted with one, two, or three substituents independently selected from the group consisting of CN, NO2, halo, \u2014ORa, \u2014C(O)Ra, \u2014C(O)ORa, \u2014OC(O)Ra, \u2014NRbRc, \u2014NRbC(O)Ra, \u2014NHC(O)NHRb, \u2014C(O)NRbRc, \u2014NHSO2Ra, and \u2014SO2NRbNRc.
4. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is aryl-C1-6-alkyl-, wherein the aryl is optionally substituted with one, two, or three substituents independently selected from the group consisting of CN, NO2, halo, \u2014ORa, \u2014C(O)Ra, \u2014C(O)ORa, \u2014OC(O)Ra, \u2014NRbRc, \u2014NRbC(O)Ra, \u2014NHC(O)NHRb, \u2014C(O)NRbRc, \u2014NHSO2Ra, and \u2014SO2NRbNRc.
5. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is C3-8 cycloalkyl-C1-6-alkyl-, wherein the cycloalkyl is optionally substituted with one, two, or three substituents independently selected from the group consisting of CN, NO2, halo, \u2014ORa, \u2014C(O)Ra, \u2014C(O)ORa, \u2014OC(O)Ra, \u2014NRbRc, \u2014NRbC(O)Ra, \u2014NHC(O)NHRb, \u2014C(O)NRbRc, \u2014NHSO2Ra, and \u2014SO2NRbNRc.
6. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 is hydrogen.
7. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R2 and R3 can be joined together to form a 5-8 membered aryl or heteroaryl ring, wherein the ring is optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-6alkyl, C1-6haloalkyl, C1-6-hydroxyalkyl, hydroxy, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2.
8. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is hydrogen or halo.
9. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is C1-6alkyl or C2-6-alkenyl, wherein the C1-6-alkyl or C2-6-alkenyl is optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of halo, hydroxy, C1-6-alkoxy, \u2014NH2, \u2014NHC1-6-alkyl, \u2014N(C1-6-alkyl)2, and \u2014C1-4alkyl-NR10R11, wherein R10 is H and R11 is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, aryl, C3-8 cycloalkyl, heteroaryl, and heterocycloalkyl.
10. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one, two, or three substituents independently selected from the group consisting of halo, C1-6alkyl, C1-6haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2.
11. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is C3-8 cycloalkyl or C3-8 cycloalkenyl, wherein the C3-8 cycloalkyl or C3-8 cycloalkenyl is optionally substituted with one, two, or three substituents independently selected from the group consisting of halo, C1-6alkyl, C1-6haloalkyl, C1-6-hydroxyalkyl, hydroxy, oxo, C1-6-alkoxy, C1-6-haloalkoxy, \u2014NH2, \u2014NH(C1-6-alkyl), and N(C1-6-alkyl)2.
12. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is C(O)R2, C(O)NR8R9, or C(O)OR2.
13. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R4 is hydrogen.
14. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein B is phenyl.
15. The compound of claim 14, or a pharmaceutically acceptable salt or solvate thereof, wherein
B is phenyl, wherein the phenyl is substituted with one, two, or three R5, and
R5, at each occurrence, is independently halo, C1-6-alkyl, C1-6 haloalkyl, ORi, cycloalkyl, heteroaryl, heterocycloalkyl, or heterocycloalkyl-C1-6-alkyl-, wherein the heterocycloalkyl, alone or as part of another moiety, is optionally substituted with one, two, or three R12; and
R12, at each occurrence, is independently C1-6-alkyl, C1-6 haloalkyl, or C(O)Rp.
16. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein B is C3-8-cycloalkyl, tetrahydronaphthyl, or indanyl, wherein the C3-8-cycloalkyl, tetrahydronaphthyl, or indanyl is optionally substituted with one, two, or three R5, and R5, at each occurrence, is independently halo, C1-6-alkyl, C1-6-haloalkyl, ORi, SRi, C(O)Ri, C(O)NRjRk, C(O)ORi, NRjRk, NRjC(O)Ri, S(O)2Ri, NRjS(O)2Ri, or S(O)2NRjRk.
17. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein B is a monocyclic heterocyclyl, wherein the heterocyclyl is a 5-7 membered heteroaryl which is optionally substituted with one, two or three R6, and R6, at each occurrence, is independently halo, C1-6-alkyl, C1-6-haloalkyl, ORl, C(O)Rl, C(O)ORl, NRmRn, or S(O)2Rl.
18. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein B is a bicyclic heterocyclyl, wherein the heterocyclyl is a 7-11 membered bicyclic heterocyclyl which is optionally substituted with one, two or three R6, and R6, at each occurrence, is independently halo, C1-6-alkyl, C1-6-haloalkyl, ORl, C(O)Rl, C(O)ORl, NRmRn, or S(O)2Rl.
19. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein B is a tricyclic heterocyclyl, wherein the heterocyclyl is a 10-15 membered tricyclic heterocyclyl which is optionally substituted with one, two or three R6, and R6, at each occurrence, is independently halo, C1-6-alkyl, C1-6-haloalkyl, ORl, C(O)Rl, C(O)ORl, NRmRn, or S(O)2Rl.
20. The compound of claim 1 of formula (I), or a pharmaceutically acceptable salt or solvate thereof, which is
ethyl 2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-6-(prop-2-en-1-yl)-5,6-dihydropyrido4,3-dpyrimidine-8-carboxylate;
ethyl 2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-6-phenyl-5,6-dihydropyrido4,3-dpyrimidine-8-carboxylate;
2-{4-(4-methylpiperazin-1-yl)phenylamino}-6-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-benzyl-N-methyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-5,6-dihydropyrido4,3-dpyrimidine-8-carboxamide;
ethyl 6-benzyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-5,6-dihydropyrido4,3-dpyrimidine-8-carboxylate;
ethyl 6-(2-chlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-5,6-dihydropyrido4,3-dpyrimidine-8-carboxylate;
ethyl 2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-5,6-dihydropyrido4,3-dpyrimidine-8-carboxylate;
6-benzyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-methylbenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
8-bromo-6-(2,6-difluorobenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(3-methylbenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-2-fluoro-6-(trifluoromethyl)benzyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-fluorobenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
2-{2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-8-phenylpyrido4,3-dpyrimidin-6(5H)-ylmethyl}benzonitrile;
6-(2-chlorobenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorobenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-4-fluorobenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(4-tert-butylbenzyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
6-2-fluoro-5-(trifluoromethyl)benzyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-phenylpyrido4,3-dpyrimidin-5(6H)-one;
ethyl 2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-8-phenylpyrido4,3-dpyrimidin-6(5H)-ylacetate;
6-(2,6-dichlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-(phenylamino)methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-8-{(2,2,2-trifluoroethyl)aminomethyl}pyrido4,3-dpyrimidin-5(6H)-one;
8-(1,3-benzothiazol-2-yl)-6-(2,6-dichlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
8-(1H-benzimidazol-2-yl)-6-(2,6-dichlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-ethenyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-ethyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}-5-oxo-5,6-dihydropyrido4,3-dpyrimidine-8-carbaldehyde;
6-(2,6-dichlorophenyl)-8-methyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-ylamino)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-{2-(dimethylamino)-2,3-dihydro-1H-inden-5-ylamino}-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-ethenyl-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6,8-dimethyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(1H-imidazol-2-yl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(fluoromethyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(hydroxymethyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
8-bromo-6-(cyclopropylmethyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
8-(cyclohex-1-en-1-yl)-6-(cyclopropylmethyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
8-(cyclopent-1-en-1-yl)-6-(cyclopropylmethyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
8-bromo-6-ethyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
8-(cyclohex-1-en-1-yl)-6-ethyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
2-{4-(4-methylpiperazin-1-yl)phenylamino}-6-phenylpyrimido5,4-cquinolin-5(6H)-one;
6-(2-chlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrimido5,4-cquinolin-5(6H)-one;
2-{4-(4-methylpiperazin-1-yl)phenylamino}-6-phenylpyrimido5,4-c1,8naphthyridin-5(6H)-one;
6-(2-chlorophenyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrimido5,4-c1,8naphthyridin-5(6H)-one;
2-amino-6-(2,6-dichlorophenyl)-8-(1H-imidazol-2-yl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-{2-(dimethylamino)-2,3-dihydro-1H-inden-5-ylamino}-8-ethenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-({44-(dimethylamino)piperidin-1-ylphenyl}amino)-8-ethenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-ylamino)-8-ethenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-ethenyl-2-{4-(hexahydropyrrolo3,4-cpyrrol-2(1H)-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(hydroxymethyl)-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-{2-(dimethylamino)-2,3-dihydro-1H-inden-5-ylamino}-8-(hydroxymethyl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-(hydroxymethyl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino-8-ethenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-ylamino)-8-(hydroxymethyl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino-8-(hydroxymethyl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-ethenyl-2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-ethenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-ethenyl-2-{4-(1-methylpiperidin-4-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-ethenyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-ethenyl-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-2-{2-(dimethylamino)-2,3-dihydro-1H-inden-5-ylamino}-8-ethenylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-methyl-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-methyl-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-2-{2-(dimethylamino)-2,3-dihydro-1H-inden-5-ylamino}-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-methyl-2-(4,4-trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-methyl-2-{4-(1-methylpiperidin-4-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-2-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-2-(2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-ylamino)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-fluorophenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-(2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(1H-imidazol-2-yl)-2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-{4-(1-methylpiperidin-4-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-{2-(dimethylamino)-2,3-dihydro-1H-inden-5-ylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-(4,4-dimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-(2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dimethylphenyl)-8-methyl-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-6-(2,6-dimethylphenyl)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-methylphenyl)-8-methyl-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-methylphenyl)-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4-{2-(dimethylamino)ethylsulfanyl}phenyl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(difluoromethyl)-2-{2-(pyrrolidin-1-yl)-2,3-dihydro-1H-inden-5-ylamino}pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4-{2-(dimethylamino)ethylsulfonyl}phenyl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
8-methyl-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)amino-6-(quinolin-8-yl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chlorophenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chlorophenyl)-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
8-methyl-6-(naphthalen-1-yl)-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-methyl-6-(naphthalen-1-yl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,5-dichlorophenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-fluoro-6-methylphenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-6-(2-fluoro-6-methylphenyl)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
8-methyl-6-2-(1,3-oxazol-5-yl)phenyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-methyl-6-2-(1,3-oxazol-5-yl)phenylpyrido4,3-dpyrimidin-5(6H)-one;
methyl 4-chloro-3-8-methyl-5-oxo-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-6(5H)-ylbenzoate;
methyl 4-chloro-3-2-({4-4-(dimethylamino)piperidin-1-ylphenyl}amino)-8-methyl-5-oxopyrido4,3-dpyrimidin-6(5H)-ylbenzoate;
6-(2,6-dichlorophenyl)-8-(fluoromethyl)-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(fluoromethyl)-2-(1,2,3,4-tetrahydroisoquinolin-6-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-({44-(dimethylamino)piperidin-1-ylphenyl}amino)-8-(fluoromethyl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-{2-(dimethylamino)-2,3-dihydro-1H-inden-5-ylamino}-8-(fluoromethyl)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(fluoromethyl)-2-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
2-(4-{6-(2,6-dichlorophenyl)-8-methyl-5-oxo-5,6-dihydropyrido4,3-dpyrimidin-2-ylamino}phenyl)sulfanyl-N-methylacetamide;
6-(2,6-dichlorophenyl)-8-methyl-2-(1,1,2-trimethyl-2,3-dihydro-1H-isoindol-5-yl)aminopyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-({4-(1-methylpiperidin-4-yl)aminophenyl}amino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-hydroxyphenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-hydroxy-6-methylphenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrido4,3-dpyrimidin-5(6H)-one;
2-(4-{6-(2,6-dichlorophenyl)-8-methyl-5-oxo-5,6-dihydropyrido4,3-dpyrimidin-2-ylamino}phenyl)sulfonyl-N-methylacetamide;
6-(2,6-dichlorophenyl)-2-(1,1-dimethyl-2,3-dihydro-1H-isoindol-5-yl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-({4-(1-methylpiperidin-4-yl)oxyphenyl}amino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-hydroxyphenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-hydroxy-6-methylphenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrido4,3-dpyrimidin-5(6H)-one;
2-(4-{6-(2,6-dichlorophenyl)-8-methyl-5-oxo-5,6-dihydropyrido4,3-dpyrimidin-2-ylamino}phenyl)sulfonyl-N-methylacetamide;
6-(2,6-dichlorophenyl)-2-(1,1-dimethyl-2,3-dihydro-1H-isoindol-5-yl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-({4-(1-methylpiperidin-4-yl)oxyphenyl}amino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(3,5-dimethyl-1H-pyrazol-4-yl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-({4-(1-methylpyrrolidin-3-yl)aminophenyl}amino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dimethylphenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2-chloro-6-methylphenyl)-8-methyl-2-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-(1-hydroxyethyl)-2-{4-(4-methylpiperazin-1-yl)phenylamino}pyrido4,3-dpyrimidin-5(6H)-one;
methyl 5-{6-(2,6-dichlorophenyl)-8-methyl-5-oxo-5,6-dihydropyrido4,3-dpyrimidin-2-ylamino}-2-(4-methylpiperazin-1-yl)benzoate;
6-(2,6-dichlorophenyl)-2-(4-{2-(dimethylamino)ethylamino}phenyl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4-{4-3-(dimethylamino)propylpiperazin-1-yl}phenyl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4-{trans-4-(dimethylamino)cyclohexylamino}phenyl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4-{cis-4-(dimethylamino)cyclohexylamino}phenyl)amino-8-methylpyrido4,3-dpyrimidin-5 (6H)-one;
7-(2,6-dichlorophenyl)-5-methyl-3-(1,2,3,4-tetrahydroisoquinolin-7-ylamino)pyrido4,3-e1,2,4triazin-8(7H)-one;
7-(2,6-dichlorophenyl)-5-methyl-3-(2\u2032-methyl-2\u2032,3\u2032-dihydro-1\u2032H-spirocyclopropane-1,4\u2032-isoquinolin-7\u2032-yl)aminopyrido4,3-e1,2,4triazin-8(7H)-one;
6-(2-chloro-6-hydroxyphenyl)-2-(1,1-dimethyl-2,3-dihydro-1H-isoindol-5-yl)amino-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-8-methyl-2-{2-(1-methylpiperidin-4-yl)-2,3-dihydro-1H-isoindol-5-ylamino}pyrido4,3-dpyrimidin-5 (6H)-one;
6-(2,6-dichlorophenyl)-2-(4-{4-2-(dimethylamino)ethylpiperazin-1-yl}phenyl)amino-8-methylpyrido4,3-dpyrimidin-5 (6H)-one;
2-(4-{4-3-(dimethylamino)propylpiperazin-1-yl}phenyl)amino-6-(2,6-dimethylphenyl)-8-methylpyrido4,3-dpyrimidin-5(6H)-one;
6-(2,6-dichlorophenyl)-2-(4-{4-3-(dimethylamino)propylpiperazin-1-yl}phenyl)amino-8-(fluoromethyl)pyrido4,3-dpyrimidin-5(6H)-one; or
6-(2,6-dichlorophenyl)-2-({2-2-(dimethylamino)ethyl-2,3-dihydro-1H-isoindol-5-yl}amino)-8-methylpyrido4,3-dpyrimidin-5(6H)-one.
21. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 1 and pharmaceutically acceptable excipient.
22. A method of treating cancer in a mammal comprising administering thereto a therapeutically acceptable amount of a compound or pharmaceutically acceptable salt thereof of claim 1.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A thin film capacitor comprising:
(a) a substrate,
(b) a first polymeric film comprising an electrically conductive polymer located on the substrate,
(c) a pentoxide layer selected from the group consisting of tantalum pentoxide, or niobium pentoxide, and mixtures thereof, and located on a surface of the first polymeric film,
(d) a second polymeric film comprising an electrically conductive polymer located on a surface of the pentoxide layer.
2. The thin film capactior of claim 1, wherein the substrate is selected from the group consisting of vinyl polymers, olefin polymers, polyesters, and mixtures thereof.
3. The thin film capacitor of claim 1, wherein the first polymeric film and the second polymeric film is selected from the group consisting of polyanilin polymers, ligno-sulfonic acid polymers, poly pyrrol polymers, thiophene-based polymers, and mixtures thereof.
4. The thin film capacitor of claim 1, wherein the first polymeric film has a thickness ranging from about 100 nanometers to about 10 micrometers.
5. The thin film capacitor of claim 1, wherein the pentoxide layer has a thickness ranging from about 10 to about 100 nanometers.
6. The thin film capacitor wherein the substrate has a thickness that is at least about 0.01 mm.
7. The thin film capacitor of claim 1, wherein the first polymeric film or the second polymeric film is selected from the group consisting of polythiophene-based polymers, polyaniline-based polymers, polypyrrole-based polymers, polyethyleneoxide-based polymers, and mixtures or copolymers thereof.
8. A thin film capacitor comprising: (a) a substrate, (b) a first polymeric conductive layer located on a surface of the substrate and (c) a plurality of alternating pentoxide layerpolymeric conductive layers extending from the first polymeric layer, wherein the total number of pentoxide layers is n and the total number of polymeric conductive layers is n1.
9. The thin film capacitor of claim 8, wherein n ranges from 1 to 30.
10. The thin film capacitor of claim 8, wherein the capacitor has a series connection.
11. The thin film capacitor of claim 8, wherein the capacitor has a parallel connection.
12. The thin film capacitor of claim 8, wherein the substrate is a non-conductive substrate selected from the group consisting of vinyl polymers, olefin polymers, polyester polymers and mixtures thereof.
13. The thin film capacitor of claim 8, wherein the substrate is selected from the group consisting of vinyl polymers, olefin polymers, polyesters, and mixtures thereof.
14. The thin film capacitor of claim 8, wherein at least one polymeric film is selected from the group consisting of polyaniline-based polymers, polypyrrole-based polymers, polyethyleneoxide-based polymers, polythiophene-based polymers, and mixtures or copolymers thereof.
15. A method for making a thin film capacitor comprising:
(a) applying a first electrically conductive polymer located on a substrate,
(b) applying a pentoxide layer, tantalum pentoxide, or niobium pentoxide, or mixtures thereof to the polymeric conductive layer, and
(c) applying a second electrically conductive polymer located on the pentoxide layer, and thereby forming a thin film capacitor.
16. The method of claim 15, wherein the thin film capacitor formed comprises:
(a) a substrate,
(b) a first polymeric film comprising an electrically conductive polymer located on the substrate,
(c) a pentoxide layer selected from the group consisting of tantalum pentoxide, or niobium pentoxide, and mixtures thereof, located on a surface of the first polymeric film,
(d) a second polymeric film comprising an electrically conductive polymer located on a surface of the pentoxide layer.
17. The method of claim 15, wherein the thin film capacitor comprises (a) a substrate, (b) a first polymeric conductive layer located on a surface of the substrate and (c) a plurality of alternating pentoxide layerpolymeric electrically conductive layers extending from the first polymeric layer, wherein the total number of pentoxide layers is n and the total number of polymeric conductive layers is n1.
18. The method of claim 15, wherein the wherein the first polymeric film and the second polymeric film is selected from the group consisting of polyaniline-based polymers, polypyrrole-based polymers, polyethyleneoxide-based polymers, polythiophene-based polymers, and mixtures or copolymers thereof.